User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

What is new in iron overload?

  • Open access
  • PDF
  • 179.91 K
  • Open access
  • PDF
  • 179.91 K
  1. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A (2006) Cardiac morbidity and mortality in deferoxamine or deferiprone-treated patients with thalassemia major. Blood 107:3733–3737
  2. Cappellini MD (2005) Iron-chelating therapy with the new oral agent ICL670 (Exjade®). Best Pract Res Clin Haematol 18:289–298
  3. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D (2006) A phase 3 study of deferasirox (ICL670), a once daily oral iron chelator, in patients with beta thalassemia. Blood 107:3455–3462
  4. Cohen AR (2006) New advances in iron chelation therapy. Hematology 2006 42–47
  5. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates T (2007) Cost effectiveness of once-daily oral chelation therapy with Deferasirox versus infusional Deferoxamine in transfusion-dependent thalassaemia patients. Pharmacoeconomics 25:329–342
  6. Fischer R, Piga A, Harmatz P, Nielsen P (2005) Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann N Y Acad Sci 1054:350–357
  7. Glickstein H, Ben El R, Shvartsman M, Cabantchik I (2005) Intracellular labile iron pools as direct targets of iron chelators : a fluorescence study of chelator action in living cells. Blood 106:3242–3250
  8. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, Perrin M, Jouanolle AM, Brissot P, Deugnier Y (2007) Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 46:587–595
  9. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, drakaki K, Kaloumenou I, Galani A, Kattamis C (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine : a 12-month trial. Blood Cell Mol Dis 36:21–25
  10. Kontoghiorghes GJ (2006) New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opin Emerging Drugs 11:1–5
  11. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107:3738–3744
  12. Stumpf JL (2007) Deferasirox. Am J Health-Syst Pharm 64:606–616
  13. Wood JC (2007) Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 14(3):183–190
Bibliographic reference Vermylen, Christiane. What is new in iron overload?. In: European journal of pediatrics, Vol. 167, no. 4, p. 377-81 (2008)
Permanent URL